{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-099444","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2022-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.548134+00:00","generated_at":"2026-06-23T09:58:30.395520+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gail Farfel named CEO of ProMIS Neurosciences effective Sept 19, 2022; Eugene Williams stays Chairman","bullets":["Gail Farfel appointed CEO effective Sept 19, 2022; Eugene Williams steps down as CEO but remains Chairman.","Dr. Farfel's base salary $500K (up to $535K after raising $75M), 50% bonus target, 208,334 stock options, $25K sign-on.","Eugene Williams to receive $225K/yr as consultant for 3 years, plus severance on signing release.","Dr. Farfel previously Chief Development Officer at Zogenix; led Fintepla Phase 3 and approvals for Dravet/LGS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-099444","json":"https://secwatch.observer/filing/0001104659-22-099444.json","markdown":"https://secwatch.observer/filing/0001104659-22-099444.md","text":"https://secwatch.observer/filing/0001104659-22-099444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/0001104659-22-099444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/tm2225652d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:58:30.395520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3ea66baafb","claim":"Eugene Williams departed as Chief Executive Officer at ProMIS Neurosciences Inc..","evidence_excerpt":"Eugene Williams, the Company’s Chief Executive Officer and principal executive officer will step down from his officer position with the Company, effective immediately","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/0001104659-22-099444-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"6a838b8052","claim":"Gail Farfel was appointed as Chief Executive Officer at ProMIS Neurosciences Inc..","evidence_excerpt":"the Board of Directors (the \" Board \") of the Company approved the appointment of Gail Farfel, Ph.D. as the Company’s Chief Executive Officer, effective September 19, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000110465922099444/0001104659-22-099444-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}